Nuvalent, Inc. 4

Nuvalent CSO Henry E. Pelish tendered 22,393 common shares and had all RSUs, PSUs, and stock options cancelled for cash at the $124.00 per‑share merger price in connection with GSK’s acquisition of Nuvalent.

On July 15, 2026, Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish had all of his Nuvalent equity awards cashed out in connection with the closing of GSK’s acquisition of the company at $124.00 per share. His 22,393 shares of Class A Common Stock were disposed of for cash at $124.00 per share, implying proceeds of roughly $2.77 million. In addition, 41,100 time‑based restricted stock units and 14,350 performance stock units were cancelled for cash consideration based on the $124.00 offer price (with the 14,350 PSUs also shown as an acquisition entry related to vesting under the merger agreement, immediately followed by their cash‑out). Multiple tranches of vested and unvested stock options, covering 3,258 shares at a $6.89 strike, 2,113 shares at $18.93, 8,309 shares at $27.85, 9,900 shares at $29.33, 21,073 shares at $72.35, 18,600 shares at $73.63, 37,500 shares at $78.09, and 17,500 shares at $106.82, were all cancelled and converted into cash equal to the intrinsic value (the spread between the $124.00 offer price and the respective exercise prices), resulting in several million dollars of additional merger consideration. Following these transactions, Pelish no longer holds Nuvalent equity, as the company became a wholly owned subsidiary of GlaxoSmithKline LLC.

Filing Facts

CIK

1861560

Ticker

NUVL

Form

4

Source Type

fda

Accession

0001193125-26-305062

Alert Tier

6